Antisense Therapeutics (ANP)
Antisense Therapeutics Ltd. is a pharmaceutical drug discovery and development company. The company's products include ATL1102 for Multiple Sclerosis, ATL1102 for Asthma, ATL1103 for Growth and Sight Disorders and ATL1101 for Prostate Cancer. It operates through the following segments: ATL 1102 - Multiple Sclerosis, and ATL 1103 - Growth and Sight Disorders. The company was founded in November 13, 2000 and is headquartered in Toorak, Australia.
|Market Price at 18-01-2018||$0.03|
|Price to Earnings Ratio||-2.09|
|Market Capitalisation||$4.85 (million)|
|Return on Equity (ROE)||-54.8%|